GlassScriptPhysician profile
Jose P Ferrer
NPI 1013975911
$11,916.62
in general payments reported to CMS, 2019-2025
42 companies · $2,215 in 2025
The $2,215 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $371 · 2021: $1,818 · 2022: $2,344 · 2023: $2,369 · 2024: $1,882 · 2025: $2,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,366 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,366.07 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,823.80 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $1,623.11 | 2019-2025 | |
| Qol Medical, LLC | $1,212.03 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $1,154.82 | 2019-2025 | Stelara, Tremfya, Erleada |
| Genzyme Corporation | $861.09 | 2022-2025 | |
| Celgene Corporation | $577.52 | 2021-2023 | Zeposia |
| Ardelyx, INC. | $507.59 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $387.29 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $378.37 | 2019-2025 | Gattex, Entyvio, Eohilia |
| Redhill Biopharma INC. | $369.24 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Ironwood Pharmaceuticals, INC | $344.57 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $340.65 | 2024-2025 | Voquezna |
| Pfizer INC. | $239.91 | 2023-2025 | |
| Nestle Healthcare Nutrition INC. | $221.44 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $218.47 | 2021-2025 | Ocaliva |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $192.30 | 2024-2025 | Iqirvo |
| Celltrion USA INC. | $170.92 | 2024-2025 | Vegzelma |
| Daiichi Sankyo INC. | $144.56 | 2019-2022 | |
| Braintree Laboratories, INC. | $111.04 | 2019-2024 | Sutab |
| Vivus LLC | $103.86 | 2021-2025 | Pancreaze, Qsymia |
| Lilly USA, LLC | $94.50 | 2024-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $92.01 | 2021-2024 | Dificid |
| Madrigal Pharmaceuticals | $81.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $61.44 | 2022-2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $57.37 | 2023 | Zeposia |
| Cumberland Pharmaceuticals, INC. | $50.52 | 2021-2022 | |
| Novo Nordisk INC | $49.93 | 2025 | Wegovy |
| Amgen INC. | $47.80 | 2021-2023 | Avsola |
| Alnylam Pharmaceuticals INC. | $47.69 | 2022-2024 | Givlaari |
| Gilead Sciences, INC. | $47.49 | 2020-2024 | |
| Mallinckrodt Hospital Products INC. | $46.65 | 2024 | Terlivaz |
| Fujifilm Healthcare Americas Corporation | $43.14 | 2023-2024 | Fujifilm |
| Exact Sciences Corporation | $39.94 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $30.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $29.51 | 2022-2023 | Andexxa |
| Pharmacosmos Therapeutics INC. | $18.22 | 2023 | Monoferric |
| Janssen Scientific Affairs, LLC | $18.19 | 2021 | |
| Aimmune Therapeutics, INC. | $17.99 | 2025 | Zenpep |
| Alfasigma USA, INC. | $17.97 | 2021 | |
| Ucb, INC. | $15.49 | 2019 | |
| Romark Laboratories, Lc | $14.47 | 2020 | |
| Pentax of America, INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Ferrer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.